Vertex Pharmaceuticals Inc., the maker of the hepatitis C drug candidate telaprevir, announced March 3 to have bought 2 additional hepatitis C drug candidates from ViroChem Pharma Inc. According to...
Hepatitis C virus (HCV) causes both acute and chronic infection. Acute HCV infections are usually asymptomatic and most do not lead to a life-threatening disease.
Rarely has a drug been introduced that represents a greater improvement in the standard of... Hepatitis C is a blood-borne virus that can live in patients for years without showing any...
Mavyret, recently approved by the Food And Drug Administration, can cure hepatitis C in eight weeks, at a cost of $26,400. Though still expensive, that's well below the price of other options.
The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected with the hepatitis C virus. The move by NHS England is unprecedented, because the...
Hepatitis C Drug Market size was valued at USD 7.86 Billion in 2018 and is projected to reach USD 7.35 Billion by 2026, exhibiting a CAGR of -0.9% during the forecast period
AUSTIN, Texas — Remdesivir is currently the only antiviral drug approved in the U.S. for treating COVID-19 patients. In a paper published this week in
Earlier this month, the Food and Drug Administration approved a class of drugs that can cure most hepatitis C infections. That's great news for the more than 3 million Americans infected. But the h...
Miller announced yesterday at the Forbes Healthcare Summit 2015 that the cost of hepatitis C drugs in the U.S. is now less than that in Europe.
Effective treatments for hepatitis C cost as much as $95,000. Medicaid in many states, including Indiana, is mostly limiting the drugs' use to very advanced cases. ACLU of Indiana is suing the state.